Life Biosciences Reports First Human Data for Cellular Reprogramming Drug ER-100 in Glaucoma

This article is based on that press release, which STAT also reported. The underlying study was not available as a paper, and the paper itself was not reviewed.

According to the release, all three participants have open-angle glaucoma. Each received a single injection into the eye at the first dose level (2×10¹¹ vg), plus daily oral doxycycline. The doxycycline switches on three genes, OCT4, SOX2 and KLF4, known together as OSK. The company says these genes reset cells to a more youthful state. An oral prednisolone taper is given to limit inflammation from the viral vector.

On safety, the release reports no dose-limiting toxicities, no adverse events of special interest and no serious adverse events. The company says every reported adverse event was related to the procedure, the steroid or a pre-existing condition, not to ER100 itself.

On vision, the release reports improvement on Humphrey visual field testing in two of the three participants at Day 56. In each, at least 28% of test points improved by more than 4 dB. The company calls these preliminary observations. It describes the trial as an open-label Phase 1 study designed to test safety and tolerability. The release describes no comparison group.

The dose-escalation decision matters most for strategy, though it is a safety-review step, not a regulatory approval. According to the release, the Data Safety Monitoring Board, the trial's safety oversight group, recommended moving to Dose Level 2 (6×10¹¹ vg), and the trial is ongoing (NCT07290244). The company also lists nonarteritic anterior ischemic optic neuropathy (NAION) as a target. The release says no treatments are currently approved for it. The Phase 1 trial began in the first quarter of 2026.

Our analysis: the release names no competitors and gives no financing details, so it cannot show where Life Bio stands against other developers. What it does show is a company-reported safety signal at the lowest dose, in three patients, over eight weeks. That is early. Any investor or rival will want to know whether the vision signals persist, whether they appear at higher doses, and whether a controlled study confirms them. The weakest point is the vision result: with three patients, no comparison group and an open-label design, it cannot be separated from chance or test variability.

Watch next for results from Dose Level 2 and for longer follow-up on the first three participants.

1. Lilly and Novo Report GLP-1 Drugs Reduced Biological Age on Molecular Aging Clocks 2. FDA Adds Aging and Longevity to Its Regulatory Science Agenda and Outlines Possible Approval Routes 3. Life Biosciences Reports First Human Data for Cellular Reprogramming Drug ER100 in Glaucoma 4. U.S. Nursing Home Operating Capacity Fell 5% Since 2019, Twice the Drop in Licensed Beds, Study Finds 5. Manulife Closes $3.2 Billion Long-Term Care Reinsurance Deal With Munich Re 6. Prestigious Nonprofit Health Systems Move Into Cash-Pay Longevity Clinics, With One Northwestern-Affiliated Package at $5,500 a Year